Tafamidis and acoramidis, two transthyretin (TTR) stabilizers, have successfully completed phase 3 clinical trials, significantly improving cardiovascular outcomes in ATTR-CM patients [1,3]. The gene discussed is TTR; the disease is cutaneous mastocytosis.